Trial Profile
A Open-label, Randomized Study of S-1 and and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Mar 2022
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 26 Feb 2022 Status changed from recruiting to completed.
- 01 Jun 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 14 May 2014 New trial record